GHK-Cu

GHK-Cu (Copper tripeptide) is a tripeptide–copper complex. The HEIVE catalog describes it as: A copper-binding tripeptide that declines with age; the best-evidenced item on this list for skin remodelling. It is also known as GHK and Copper peptide.

HEIVE groups GHK-Cu under skin health, skin aesthetics, hair, tissue repair and cellular maintenance. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for GHK-Cu under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products. FDA describes safety concerns or insufficient safety information for the corresponding substance on its compounding-risk page; that listing is not a drug approval. Cosmetic use is separate: FDA generally does not preapprove cosmetics or cosmetic ingredients, except certain color additives.

• FDA product data (October 6, 2026)
• FDA compounding safety information
• FDA cosmetics policy

The HEIVE editorial risk summary for GHK-Cu lists: Blue-green staining at the site; stinging on broken skin. Longer-term concerns: Copper accumulation with high-dose systemic use over months. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

GHK-Cu has no single onset time established by this catalog. The editorial timeline starts with “Days 1–7”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for GHK-Cu: Topical 1–3% daily; injected 1–2 mg daily is far less studied. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies GHK-Cu as having human research. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists topical for GHK-Cu. A listed form is not evidence of an approved or effective treatment.

Preparation of GHK-Cu depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for GHK-Cu depends on the specific formulation (injectable and topical in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for GHK-Cu: None described at topical doses. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

GHK-Cu and TB-500 share the catalog categories tissue repair, skin health and hair. GHK-Cu: A copper-binding tripeptide that declines with age; the best-evidenced item on this list for skin remodelling. TB-500: An actin-binding fragment associated with cell migration and blood-vessel formation in injured tissue. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View TB-500

The HEIVE editorial summary highlights: Gene-expression work found it resets a large block of genes toward a younger profile — an accident of its copper binding. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.